

Rhomboid antigens are promising targets in the vaccine development against *Toxoplasma gondii*

[Article - PDF](#)**Published** May 21, 2019**DOI** <https://doi.org/10.17179/excli2018-1993>**Masoud Foroutan**

Abadan School of Medical Sciences, Abadan, Iran; Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Leila Zaki

Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Sanaz Tavakoli

Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Shahrzad Soltani

Abadan School of Medical Sciences, Abadan, Iran

Ali Taghipour

Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Fatemeh Ghaffarifar

Department of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, P.O. Box 14115-111, Iran, Tel: +98-21-82884553, Fax: +98-21-82884555, E-mail: ghafarifar@modares.ac.ir

Abstract

Toxoplasma gondii (*T. gondii*) is an obligate intracellular parasite with worldwide distribution. It is estimated that near one-third of the people around the globe are latently seropositive for the parasite. Since the current common drugs are incapable in the elimination of parasites within tissue cysts, the development of an effective vaccine has high priority for researchers to limit the infection. During recent years, non-stop efforts of scientists have made great progress in the identification and development of *T. gondii* candidate vaccines. However, there is a lack of a commercially licensed vaccine for human application yet. Rhomboid proteases (ROMs) are a class of serine proteases that have an important role in the invasion of the parasites that can be *considered as a new target for vaccine strategy*. They also play critical roles in mitochondrial fusion and growth factor signaling, allowing the parasite to completely enter into the host cell. In the current review, we have summarized the recent progress regarding the development of ROM-based vaccines against acute and chronic *T. gondii* infection in animal models.

How to Cite

Foroutan, M., Zaki, L., Tavakoli, S., Soltani, S., Taghipour, A., & Ghaffarifar, F. (2019). Rhomboid antigens are promising targets in the vaccine development against *Toxoplasma gondii*. *EXCLI Journal*, 18, 259-272.
<https://doi.org/10.17179/excli2018-1993>

[More Citation Formats ▾](#)

Issue

[Vol 18 \(2019\)](#)

Section

Review articles



This work is licensed under a [Creative Commons Attribution 4.0 International License](#).

Authors who publish in this journal agree to the following terms:

- The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, [CC BY 4.0](#). This licence permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
- The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
- Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
- The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).

Powered by



LEIBNIZ RESEARCH CENTRE
FOR WORKING ENVIRONMENT
AND HUMAN FACTORS

[Make a Submission](#)

USER

Username

Password

☐ Remember me

[Login](#)

JOURNAL CONTENT

Search

Search Scope

All

[Search](#)

BROWSE

[By Issue](#)

[By Author](#)

EXCLI Journal has been added to

[Directory of Open Access Journals \(DOAJ\)](#)

[Electronic Journals Library \(EZB\)](#)

[Web of Science](#)

[SCOPUS](#)

[Pubmed Central](#)

[Pubmed](#)

[EBSCO Academic Search](#)

[SCImago](#)

[LIVIVO](#)

[BASE](#)

Impact Factor

2013: 0.728

2014: 0.857

2015: 1.292

2016: 1.462

2017: 2.424

EXCLI Journal is a platinum open access journal. There are neither fees for authors submitting their papers nor fees for readers accessing PDFs of the published papers.

Articles published in EXCLI Journal are licensed under a [Creative Commons Attribution 4.0 International License](#).

